Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CHANTIX

« Back to Dashboard
Chantix is a drug marketed by Pfizer Inc and is included in one NDA. It is available from seven suppliers. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-eight patent family members in fifty-five countries.

The generic ingredient in CHANTIX is varenicline tartrate. There are five drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

Summary for Tradename: CHANTIX

Suppliers / Packagers: see list23

Pharmacology for Tradename: CHANTIX

Clinical Trials for: CHANTIX

Varenicline as a Treatment for Methamphetamine Dependence
Status: Completed Condition: Methamphetamine Dependence; Methamphetamine Abuse; Substance Abuse

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder
Status: Completed Condition: Smoking Cessation; Bipolar Disorder

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.
Status: Completed Condition: Smoking Cessation

Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers
Status: Completed Condition: Depressive Disorder; Smoking

Tailoring Varenicline to Individual Needs (TVIN Study)
Status: Completed Condition: Tobacco Dependence; Smoking Cessation

Varenicline for Smoking Cessation in Heavy Drinking Smokers
Status: Completed Condition: Nicotine Dependence; Smoking; Heavy Drinking

Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation
Status: Not yet recruiting Condition: Nicotine Dependence

Assessing the Impact of Varenicline on Brain-Behavior Vulnerability
Status: Active, not recruiting Condition: Varenicline and the Blunting of Cocaine Cues

Varenicline In-Patient Study
Status: Completed Condition: Smoking Cessation

Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study)
Status: Completed Condition: Tobacco Dependence; Smoking Cessation

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXNo6,410,550<disabled>YY <disabled>
Pfizer Inc
varenicline tartrate
TABLET;ORAL021928-002May 10, 2006RXYes6,410,550<disabled>YY <disabled>
Pfizer Inc
varenicline tartrate
TABLET;ORAL021928-001May 10, 2006RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CHANTIX

Drugname Dosage Strength RLD Submissiondate
varenicline tartrateTablets0.5 mg and 1 mgChantix5/10/2010

International Patent Family for Tradename: CHANTIX

Country Document Number Publication Date
China1285821Feb 28, 2001
European Patent Office1392307Mar 03, 2004
Guatemala199800200Jun 07, 2000
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn